AstraZeneca and Chi-Med begin Phase III trial of savolitinib for PRCC

AstraZeneca and Hutchison China MediTech (Chi-Med) have started a Phase III SAVOIR clinical trial of savolitinib to treat patients with papillary renal cell carcinoma (PRCC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news